Dr. Bellmunt on PD-L1 Data in Bladder Cancer

Video

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses PD-L1 data with pembrolizumab (Keytruda) in patients with bladder cancer.

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses PD-L1 data with pembrolizumab (Keytruda) in patients with bladder cancer.

The way that PD-L1 is being scored with pembrolizumab in patients with bladder cancer is different than scores being used for other drugs, such as atezolizumab (Tecentriq), says Bellmunt. For pembrolizumab, physicians are using staining in tumor cells and immune cells divided by the number of tumor cells. In the initial report of the study, it was established that a patient with a score of more than 10% might derive benefit from pembrolizumab, says Bellmunt.

However, there was not a difference in patients who had a PD-L1—positivity score of more than 10%. The benefit was there and the hazard ratio was much better, but there was no change in terms of median survival or in terms of substantial improvement, explains Bellmunt. Therefore, PD-L1 in the pembrolizumab-treated patients does not seem to impact therapeutic decision.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,